Last reviewed 2026-05-25 · How we verify

Vigamox Eye Drops

Vigamox Eye Drops is a Fluoroquinolone antibiotic Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer. Also known as: Vigamox(moxifloxacin hydrochloride ophthalmic solution).

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.

Vigamox Eye Drops are used to treat various eye conditions, including Acute Bacterial Conjunctivitis, Bacterial Infections, and Eye Infections, as well as Cataract and Meibomian Gland Dysfunction. The active ingredient in Vigamox Eye Drops is Moxifloxacin HCl 0.5%, which is delivered in a solution form.

At a glance

Mechanism of action

Moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This dual inhibition prevents bacterial DNA from unwinding and replicating, leading to rapid bactericidal activity. The ophthalmic formulation delivers high local concentrations to the eye to treat bacterial infections of the ocular surface.

Approved indications

• Bacterial conjunctivitis
• Bacterial keratitis
• Bacterial corneal ulcer

Common side effects

• Conjunctival hyperemia
• Eye irritation
• Ocular discomfort
• Taste perversion

Key clinical trials

• IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING (NA)
• Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis (NA)
• PRO-232 in Patients Subjected to Cataract Surgery (PHASE3)
• Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II (PHASE3)
• Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
• Dropless Pars Plana Vitrectomy Study (PHASE4)
• Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects (PHASE1)
• Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Vigamox Eye Drops CI brief — competitive landscape report
• Vigamox Eye Drops updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI

Frequently asked questions about Vigamox Eye Drops

Related

• Drug class: All Fluoroquinolone antibiotic drugs
• Target: All drugs targeting Bacterial DNA gyrase and topoisomerase IV
• Manufacturer: Merck Sharp & Dohme LLC — full pipeline
• Therapeutic area: All drugs in Ophthalmology / Infectious Disease
• Indication: Drugs for Bacterial conjunctivitis
• Indication: Drugs for Bacterial keratitis
• Indication: Drugs for Bacterial corneal ulcer
• Also known as: Vigamox(moxifloxacin hydrochloride ophthalmic solution)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing